| BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; BMN 307, an AAV5 mediated gene therapy, which is in phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; BMN 331 for the treatment of hereditary angioedema; BMN 255 for the treatment of chronic renal disease; and BMN 351 for the treatment of Duchenne Muscular Dystrophy. The company has collaboration and license agreements with Sarepta Therapeutics, Asubio Pharma Co., Ltd., and DiNAQOR AG. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. was incorporated in 1996 and is headquartered in San Rafael, California. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Davis George Eric | EVP, General Counsel | Apr 19 | Option Exercise | 26.49 | 2,709 | 71,761 | 71,149 | Apr 20 09:53 PM | | Davis George Eric | EVP, General Counsel | Apr 19 | Sale | 79.58 | 2,709 | 215,582 | 68,440 | Apr 20 09:53 PM | | LAWLIS V BRYAN | Director | Apr 15 | Option Exercise | 26.49 | 7,500 | 198,675 | 26,350 | Apr 19 04:09 PM | | LAWLIS V BRYAN | Director | Apr 15 | Sale | 76.90 | 7,500 | 576,750 | 18,850 | Apr 19 04:09 PM | | Ajer Jeffrey Robert | EVP, Chief Commercial Officer | Apr 08 | Sale | 78.81 | 1,537 | 121,131 | 58,250 | Apr 09 05:57 PM | | Mueller Brian | EVP, Chief Financial Officer | Apr 01 | Sale | 76.30 | 5,692 | 434,300 | 31,016 | Apr 02 07:35 PM | | Ajer Jeffrey Robert | EVP, Chief Commercial Officer | Mar 24 | Sale | 76.30 | 1,181 | 90,110 | 61,439 | Mar 26 05:45 PM | | Ajer Jeffrey Robert | EVP, Chief Commercial Officer | Mar 18 | Sale | 77.99 | 1,308 | 102,011 | 64,133 | Mar 19 09:01 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Mar 12 | Option Exercise | 26.49 | 7,000 | 185,430 | 302,652 | Mar 15 08:26 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Mar 12 | Sale | 77.10 | 7,000 | 539,700 | 295,652 | Mar 15 08:26 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Mar 11 | Option Exercise | 26.49 | 7,000 | 185,430 | 302,652 | Mar 15 08:26 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Mar 11 | Sale | 77.68 | 7,000 | 543,760 | 295,652 | Mar 15 08:26 PM | | GREY MICHAEL G | Director | Mar 05 | Option Exercise | 26.49 | 5,000 | 132,450 | 47,840 | Mar 09 05:59 PM | | GREY MICHAEL G | Director | Mar 05 | Sale | 76.28 | 5,000 | 381,400 | 42,840 | Mar 09 05:59 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Feb 19 | Option Exercise | 26.49 | 7,000 | 185,430 | 302,552 | Feb 22 08:38 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Feb 19 | Sale | 83.58 | 7,000 | 585,060 | 295,552 | Feb 22 08:38 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Feb 18 | Option Exercise | 26.49 | 7,000 | 185,430 | 302,552 | Feb 19 09:22 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Feb 18 | Sale | 85.08 | 7,000 | 595,560 | 295,552 | Feb 19 09:22 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Feb 17 | Option Exercise | 26.49 | 8,000 | 211,920 | 303,552 | Feb 18 09:45 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Feb 17 | Sale | 84.54 | 8,000 | 676,320 | 295,552 | Feb 18 09:45 PM | | LAWLIS V BRYAN | Director | Feb 16 | Option Exercise | 26.49 | 7,500 | 198,675 | 26,350 | Feb 18 06:43 PM | | LAWLIS V BRYAN | Director | Feb 16 | Sale | 87.41 | 7,500 | 655,575 | 18,850 | Feb 18 06:43 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Jan 29 | Option Exercise | 26.49 | 8,334 | 220,768 | 303,886 | Feb 01 07:00 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Jan 29 | Sale | 82.67 | 8,334 | 688,972 | 295,552 | Feb 01 07:00 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Jan 28 | Option Exercise | 26.49 | 8,333 | 220,741 | 303,885 | Feb 01 07:00 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Jan 28 | Sale | 82.91 | 8,333 | 690,889 | 295,552 | Feb 01 07:00 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Jan 27 | Option Exercise | 26.49 | 8,333 | 220,741 | 303,885 | Jan 28 07:35 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Jan 27 | Sale | 85.49 | 8,333 | 712,388 | 295,552 | Jan 28 07:35 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Dec 29 | Sale | 88.18 | 1,500 | 132,270 | 295,552 | Dec 30 08:02 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Dec 28 | Sale | 88.77 | 1,500 | 133,155 | 297,052 | Dec 30 08:02 PM | | Ajer Jeffrey Robert | EVP, Chief Commercial Officer | Oct 14 | Sale | 79.91 | 2,121 | 169,489 | 61,281 | Oct 15 07:17 PM | | HERON ELAINE J | Director | Oct 07 | Option Exercise | 26.49 | 15,000 | 397,350 | 66,968 | Oct 08 08:35 PM | | PYOTT DAVID E I | Director | Aug 31 | Buy | 78.26 | 12,800 | 1,001,715 | 30,740 | Sep 01 09:44 PM | | GREY MICHAEL G | Director | Aug 03 | Option Exercise | 26.49 | 2,500 | 66,225 | 45,340 | Aug 05 06:56 PM | | GREY MICHAEL G | Director | Aug 03 | Sale | 120.35 | 2,500 | 300,875 | 42,840 | Aug 05 06:56 PM | | FUCHS HENRY J | President, Worldwide R&D | Jul 20 | Option Exercise | 65.97 | 126,389 | 8,337,656 | 229,384 | Jul 22 05:32 PM | | FUCHS HENRY J | President, Worldwide R&D | Jul 20 | Sale | 130.00 | 126,389 | 16,430,570 | 102,995 | Jul 22 05:32 PM | | FUCHS HENRY J | President, Worldwide R&D | Jul 13 | Option Exercise | 65.97 | 23,011 | 1,518,094 | 126,006 | Jul 15 09:32 PM | | FUCHS HENRY J | President, Worldwide R&D | Jul 13 | Sale | 130.00 | 23,011 | 2,991,430 | 102,995 | Jul 15 09:32 PM | | Dere Willard H | Director | Jun 26 | Sale | 123.61 | 4,430 | 547,592 | 13,290 | Jun 30 02:11 PM | | Ajer Jeffrey Robert | EVP, Chief Commercial Officer | Jun 19 | Option Exercise | 63.10 | 15,000 | 946,500 | 78,402 | Jun 23 07:24 PM | | Ajer Jeffrey Robert | EVP, Chief Commercial Officer | Jun 19 | Sale | 124.00 | 15,000 | 1,860,000 | 63,402 | Jun 23 07:24 PM | | LAWLIS V BRYAN | Director | Jun 05 | Sale | 107.46 | 4,430 | 476,048 | 18,850 | Jun 09 06:04 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | May 08 | Option Exercise | 21.51 | 20,000 | 430,200 | 318,552 | May 12 01:51 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | May 08 | Sale | 91.72 | 20,000 | 1,834,400 | 298,552 | May 12 01:51 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | May 04 | Option Exercise | 21.51 | 5,000 | 107,550 | 303,552 | May 05 07:22 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | May 04 | Sale | 88.00 | 5,000 | 440,000 | 298,552 | May 05 07:22 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | May 01 | Option Exercise | 21.51 | 4,000 | 86,040 | 302,552 | May 05 07:22 PM | | Davis George Eric | EVP, General Counsel | May 01 | Sale | 89.38 | 12,504 | 1,117,608 | 65,677 | May 04 09:45 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | May 01 | Sale | 89.38 | 4,000 | 357,520 | 298,552 | May 05 07:22 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Apr 28 | Option Exercise | 21.51 | 20,000 | 430,200 | 318,213 | Apr 29 07:40 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Apr 28 | Sale | 97.58 | 20,000 | 1,951,600 | 298,213 | Apr 29 07:40 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Apr 27 | Option Exercise | 21.51 | 20,000 | 430,200 | 318,213 | Apr 29 07:40 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Apr 27 | Sale | 97.73 | 20,000 | 1,954,600 | 298,213 | Apr 29 07:40 PM | | FUCHS HENRY J | President, Worldwide R&D | Apr 24 | Sale | 95.88 | 20,000 | 1,917,617 | 102,656 | Apr 28 02:37 PM |
|
